Can a targeted drug boost Chemotherapy's power against a rare lymphoma?
NCT ID NCT07753642
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy can improve outcomes for people with a rare type of lymphoma called nodal T-follicular helper cell lymphoma. The study will include about 47 adults who have not yet received treatment for this disease. The main goal is to see how many patients achieve complete remission after the initial treatment, while also monitoring safety and long-term effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- golidocitinib combined with an anthracycline-based chemotherapy regimen (doxorubicin or epirubicin)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for nodal TFH cell lymphoma, potentially improving remission rates and long-term outcomes.
- What could go wrong
- This is a phase II trial with a small number of participants, so results may not be conclusive. The combination may cause side effects, and its effectiveness compared to standard care is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 47 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key inclusion Criteria: 1. Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification. 2. Previously untreated with systemic anti-lymphoma therapy. 3. Age ≥18 and \<75 years. 4. At least one measurable or evaluable lesion according to the Lugano 2014 criteria. 5. An expected survival time of more than 12 weeks. 6. An ECOG performance status score of 0-1. 7. Adequate organ and bone marrow function. 8. Provision of written informed consent and willingness to comply with all study procedures. Key exclusion Criteria: 1. Hemophagocytic syndrome. 2. Central nervous system or meningeal involvement by lymphoma. 3. Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin. 4. Patients receiving potent CYP3A inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants. 5. Patients with active infections, including tuberculosis, HIV infection, active hepatitis B, or active hepatitis C. 6. Patients with severe or uncontrolled cardiovascular disease. 7. Patients with a history of interstitial lung disease, except for asymptomatic radiation-induced interstitial lung disease. 8. Patients with gastrointestinal conditions that may interfere with oral administration or drug absorption. 9. Patients with known hypersensitivity to golidocitinib or its excipients. 10. Pregnant or breastfeeding women and participants of childbearing potential unwilling to use effective contraception. 11. Patients who have received systemic corticosteroids or other immunosuppressive therapy within 14 days before the start of study treatment. 12. Patients considered unsuitable for participation by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nodal T-follicular helper cell lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, Guangdong, 51000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.